Latest / AVBCC Value-Based Voices / Ted Slafsky on 340B's Triple Threat: CMS Cuts, the Rebate Model Fight & Contract Pharmacy in Court
Transcript
- 0:00SPEAKER_00: Welcome to Value-Based Voices, a podcast from the Association for Value-Based Cancer Care.
- 0:05SPEAKER_00: Each episode dives into the shifting terrain of cancer care in the United States, exploring what value means in today's clinical, policy, and patient-centered environments.
- 0:15SPEAKER_00: Our mission is to spark informed dialogue, promote transparency, and equip every stakeholder with the insight they need to navigate cancer care with clarity, confidence, and purpose.
- 0:31SPEAKER_00: My name is Jason Sonic, and I'm joined today by Ted Slavski from the 340B Report.
- 0:36SPEAKER_00: During today's episode, we're going to get an update on three prominent issues impacting the 340B program.
- 0:42SPEAKER_00: First, CMS's recent decision to reduce the reimbursement rate from ASP plus 6 to ASP minus 28 to cover entities and certain other hospitals for drugs purchased at the 340B.
- 0:55SPEAKER_00: This is very timely.
- 0:56SPEAKER_00: We just heard this decision from CMS.
- 0:59SPEAKER_00: We really appreciate Ted joining us.
- 1:01SPEAKER_00: Number two, Ted's going to give us an update on the litigation on the 340B rebate model.
- 1:06SPEAKER_00: And finally, we're going to discuss the latest doings on contract pharmacy, all of which are going to wind up in litigation.
- 1:13SPEAKER_00: And stay tuned for Ted's predictions on how all the litigation is going to shake out.
- 1:19SPEAKER_00: It is an honor to welcome uh Ted Slavsky to this call.
- 1:24SPEAKER_00: I'm going to let him introduce himself in a few minutes, but uh, as you will hear, he's the editor-in-chief of something called the 340B Report.
- 1:33SPEAKER_00: And I've been reading the 340B report for years.
- 1:36SPEAKER_00: I mean, you you wouldn't look at it from Ted uh uh about how long it's been.
- 1:41SPEAKER_00: He looks great, by the way.
- 1:42SPEAKER_00: Um, it is the only place to get information on 340B, no matter where you sit on the spectrum about the 340B issues that we're going to discuss with 340B Red Large.
- 1:52SPEAKER_00: I can't strongly recommend enough um reading and accessing the 340B reports, the podcasts, the slide decks, everything that Ted puts out is really great information.
- 2:03SPEAKER_00: And we really appreciate you coming today and sharing some of your insight on three major policy issues that have that have occurred or ongoing really over the last, let's call it, eight to ten months.
- 2:16SPEAKER_00: Um, number one, uh, just so everybody knows that Ted and I are going to talk about happened last Wednesday.
- 2:21SPEAKER_00: It's hot off the press, and why we really appreciate your time, Ted, uh, which relates to the reduction of the hospital reimbursement rate for drugs purchased at 340B.
- 2:30SPEAKER_00: Number two is to continue to talk about the rebate model, uh, which will uh give some further detail in a few minutes.
- 2:37SPEAKER_00: And then number three, what's going on in in contract pharmacy.
- 2:40SPEAKER_00: So we have a lot to cover on this uh issue, and we really appreciate your time, Ted.
- 2:45SPEAKER_00: So you weren't always involved with the 340B report, right?
- 2:50SPEAKER_00: There was a life prior to 340B, a very impressive one, I might add.
- 2:54SPEAKER_00: So, Ted, why don't you start with a few words about yourself and how you came to the 340B report?
- 3:00SPEAKER_01: Sure, that's right, Jason.
- 3:02SPEAKER_01: Um actually began my career as a journalist.
- 3:05SPEAKER_01: Um I uh actually started very early.
- 3:08SPEAKER_01: I was the uh managing editor of my high school newspaper and then was the sports editor of my college newspaper at Tufts University, and then um decided to pursue a career in journalism and worked at U.S.
- 3:22SPEAKER_01: News and World Report for close to four years.
- 3:25SPEAKER_01: I had a great mentor there, David Gergen.
- 3:28SPEAKER_01: Uh, David, as you may know, Jason, was an advisor to four U.S.
- 3:33SPEAKER_01: presidents, both Democrats and Republicans, um, and was a wonderful um uh mentor to me over the years.
- 3:41SPEAKER_01: And I talked to him about maybe moving to a career of public service.
- 3:46SPEAKER_01: And uh he happened to be from Durham, North Carolina, and his father was a professor at a university called Duke University.
- 3:54SPEAKER_01: So I ended up there at Duke for two years, and during my time at Duke, um, it was in the sort of the whole battle over trying to get the Clinton Healthcare Reform Initiative enacted.
- 4:07SPEAKER_01: And I had the pleasure of working for uh Senate Majority Leader George Mitchell and Tom Dashell, who was the uh deputy um leader of the Senate Democrats at the time.
- 4:20SPEAKER_01: And we tried um and failed to enact the uh healthcare, um the big Clinton Healthcare Reform Initiative, with Hillary Clinton playing a big role in that initiative.
- 4:31SPEAKER_01: Um, but it was a great experience um and uh got to meet a lot of folks on both sides of the aisle and decided I would be an advocate.
- 4:41SPEAKER_01: Um, started working for what uh was now called 340B Health.
- 4:47SPEAKER_01: It used to have another name.
- 4:48SPEAKER_01: It's the trade group for the hospitals in the 340B program.
- 4:52SPEAKER_01: And I was there for 22 years um working on all the different advocacy issues, getting to know lawmakers and policymakers.
- 5:02SPEAKER_01: And um, I was the CEO there for over 10 years.
- 5:06SPEAKER_01: And then in 2018, I pivoted um and uh decided after a little while of contemplation to begin a news service on the 340B program.
- 5:18SPEAKER_01: And it's grown tremendously, our newsletter.
- 5:21SPEAKER_01: Um, we have lots of subscribers from all different stakeholders in the 340B world, from both the provider side, drug industry, lawyers, um, uh good lobbyists like you, um, who depend on the 340B report for all things 340B.
- 5:41SPEAKER_01: And we're really proud of the work that we're doing covering this very complicated but important program.
- 5:47SPEAKER_00: Yeah, I mean, uh agreed.
- 5:49SPEAKER_00: Thank you for that wonderful introduction.
- 5:51SPEAKER_00: You got uh really had the opportunity to work with some real lens lions of the Senate, right?
- 5:56SPEAKER_00: Some real adults.
- 5:57SPEAKER_00: And again, no matter where you sit, we we we miss some of those kinds of adult supervision uh these days.
- 6:04SPEAKER_00: Uh and going forward, it'd be it'd be great to find some some more of those.
- 6:08SPEAKER_00: And um you bring a lot of history here, a lot of important history, not only from a health policy point of view, but from a journalistic point of view and and well trained.
- 6:18SPEAKER_00: And so that's why, you know, I I appreciate the uh and go to the 340B report.
- 6:23SPEAKER_00: I want to sort of dive in.
- 6:26SPEAKER_00: One of the major issues you've been covering is what is happening at the reimbursement rate at the hospital.
- 6:31SPEAKER_00: Uh, by way of background, for our listeners who may not be aware, um, this is not the first time, but this is the second time now that CMS has finalized a reduction to the reimbursement rate for drugs purchased at the at a covered entity.
- 6:46SPEAKER_00: Uh more specifically, CMS finalized an ASP minus 28% rate for most hospitals, for most drugs.
- 6:55SPEAKER_00: There are exceptions in terms of, as I hinted, types of hospitals, exempt hospitals, children's hospitals, and no pain act drugs and pass-through drugs, but the overwhelming majority of both hospitals dish and non-pass-through separately paid drugs are now subject to an ASP minus 28 reduction starting January 1.
- 7:16SPEAKER_00: And this policy just came out last week.
- 7:18SPEAKER_00: You guys are getting this hot off the press.
- 7:20SPEAKER_00: The first time this happened was during the first Trump administration, and the hospitals litigated and created a huge mess with a clawback, whatever, we might get into that in a minute.
- 7:30SPEAKER_00: But Ted, you've got your finger on the pulse.
- 7:33SPEAKER_00: What are the, I mean, most of us who are not as close to the hospital, certainly with their common letter and the way CMS responded, anticipate the hospitals to litigate.
- 7:42SPEAKER_00: What are your spidey senses telling you related to the litigation and when we might expect it?
- 7:47SPEAKER_01: Sure.
- 7:48SPEAKER_01: Um that that's a good history lesson, Jason.
- 7:51SPEAKER_01: Um, it seems like it's deja vu all over again.
- 7:54SPEAKER_01: Um it is uh uh as uh Jason referenced, there was actually a big Supreme Court decision um back, I think it was in maybe 2020 or so, 2018, uh 2022.
- 8:08SPEAKER_01: Thank you.
- 8:09SPEAKER_01: Thank you, Jason, for uh your great memory that overturned the cuts.
- 8:14SPEAKER_01: Um and uh there have been uh efforts to reimburse the uh hospitals that were received these cuts um over the last few years.
- 8:24SPEAKER_01: Um and um now we have this new proposal, which um is a very big cut um to the 340B hospitals.
- 8:33SPEAKER_01: I do expect there to be another lawsuit.
- 8:36SPEAKER_01: Probably uh the same folks who are suing now, uh sued last time will sue again, which would be a variety of hospital associations that are based here in Washington, where you and I are based, Jason.
- 8:50SPEAKER_01: Um, and um whether they will be as successful uh this time around.
- 8:56SPEAKER_01: They had a slam duck victory last time.
- 8:59SPEAKER_01: It took a while, but uh the certainly the the U.S.
- 9:02SPEAKER_01: Supreme Court fa ruled in their favor.
- 9:04SPEAKER_01: That is uh an open question.
- 9:06SPEAKER_01: And feel free to ask me more about the nuances of that if you'd like.
- 9:10SPEAKER_00: Right, so Tell let's dive into that.
- 9:12SPEAKER_00: I appreciate that opening.
- 9:14SPEAKER_00: Um So you mentioned, right, the first time around, slam dunk.
- 9:19SPEAKER_00: I mean, I make the jokes about the, I mean, it was slam dunk, right?
- 9:22SPEAKER_00: You guys didn't do the survey.
- 9:23SPEAKER_00: Survey says, right, in honor of may you rest in peace, Richard Dostamer.
- 9:27SPEAKER_00: We're of the same age, we know who that is, right?
- 9:29SPEAKER_00: These guys didn't do the survey.
- 9:30SPEAKER_00: They show up in the beginning of this administration, they say they're gonna do a survey, they do the survey.
- 9:35SPEAKER_00: Now they've done the survey, and we'll get into that in a minute.
- 9:38SPEAKER_00: So, yes, the hospitals are gonna sue.
- 9:41SPEAKER_00: Do you have a sense on sort of like how much is their legal case stronger now?
- 9:46SPEAKER_00: And are they gonna see conjunctive relief?
- 9:48SPEAKER_00: And do you think this goes into effect January 1?
- 9:51SPEAKER_00: So let's take those in turn.
- 9:53SPEAKER_00: Um, what do you uh what are their causes of action gonna be?
- 9:56SPEAKER_00: Sure.
- 9:57SPEAKER_01: Now keep in mind, um, unlike you, Jason, who you have a law degree, I just pretend to have a law degree.
- 10:04SPEAKER_00: So there's a very thin-line difference here, Ted, trust me.
- 10:07SPEAKER_01: I could say my brother's a lawyer.
- 10:09SPEAKER_01: Um, but um I do they they are um they're very likely uh to sue, and they're gonna uh likely try to block it altogether through some sort of injunctive relief.
- 10:23SPEAKER_01: Um and they may not have as strong a case this time, um, because um it is true that CMS did conduct a survey this time.
- 10:34SPEAKER_01: Now, as as think as you're aware, my understanding is that they ended up using data from HERSA, the ceiling price data, rather than the survey results um to determine the reduction in reimbursement.
- 10:51SPEAKER_01: So I'm not entirely sure if um they will actually have a case here, and they might um because they didn't end up using the survey results.
- 11:03SPEAKER_01: So I don't know for sure whether they will be successful, but I can guarantee you they're gonna try um just because it's a uh a significant cut in reimbursement, um, one that um the hospitals believe is unfair and that will result in um undermining patient care.
- 11:24SPEAKER_01: Um and we're I'm happy to talk more about that.
- 11:27SPEAKER_01: Um, but there there is certainly going to be another effort um to try to block uh this just this recent action that occurred just last week.
- 11:37SPEAKER_00: Yeah, it's very when you read the preamble, there is some really pointed language.
- 11:42SPEAKER_00: I don't know, Ted, if you had a chance to digest what what the you know the common response that is in every final rule related to this policy in particular.
- 11:51SPEAKER_00: Uh and they get the agency tries to say some of that, right?
- 11:55SPEAKER_00: And I agree.
- 11:55SPEAKER_00: At first I thought they have to, but they are bound by the survey and it said for that drug for that year, and SEMAS sort of responds, look, well, we read the statute this way to say that the reimbursement rate is for that drug.
- 12:10SPEAKER_00: ASP methodology 28, we comply there, and then survey taking into account the language in the statute allows them to bring in Hearse's data.
- 12:20SPEAKER_00: And we took into account 33 and we we landed at 28.
- 12:24SPEAKER_00: So I agree.
- 12:25SPEAKER_00: It's gonna be, it's not as much of a slam dunk had they not done the survey.
- 12:30SPEAKER_00: And then the other part that the agencies talk about is this sort of promotion, this program about the hospitals not responding and then the survey rate.
- 12:41SPEAKER_00: And then CMS sort of says, well, you guys, the hospitals you're promoting not responding, and now you can't complain about a low response rate.
- 12:50SPEAKER_00: What do you what would what was your reaction when you saw that, that kind of back and forth that CMS talks, at least describes in the preamble related to the comments that they received on the on their 33.4 negative response uh proposal?
- 13:04SPEAKER_01: Yeah, I mean, I think what the trade associations are arguing, and I'm uh a former CEO of one of those trade groups, uh, so that is uh full disclosure as we discussed.
- 13:16SPEAKER_01: Um, I think that they're arguing that um that survey was not uh required.
- 13:23SPEAKER_01: You're not required to respond to the survey.
- 13:26SPEAKER_01: There is some dispute over whether there is an actual requirement to actually have submitted data to the contractors that were working with CMS on collecting the data.
- 13:38SPEAKER_01: Um and you are correct that the uh there was not a large uh response rate from those hospitals in the 340B program, much uh larger from the non-340B hospitals.
- 13:50SPEAKER_01: Um and uh whether that is um gonna be a big factor in the decision will be uh will be interesting to see.
- 14:00unknown: All right.
- 14:00SPEAKER_00: We'll leave it up to somebody who's a lot smarter than we are at the judicial uh branch to sort of uh parse that piece out, as well as some other, I'm sure, um, important like statutory interpretations about relevant characteristics and everything else we talked about.
- 14:17SPEAKER_00: But for our listeners who really, I mean, this is real weedsy but nerdy and nerdy, but it is kind of interesting to see how CMS and the hospitals are going at each other on this issue of, like you said, it wasn't required and the survey and all of that.
- 14:32SPEAKER_00: So it's it's gonna be very interesting to see how the how a judge and a court um respond to that.
- 14:39SPEAKER_00: I personally think I agree that they're they're gonna sue.
- 14:41SPEAKER_00: I don't know that they're gonna get injunctive relief.
- 14:44SPEAKER_00: Um, right?
- 14:45SPEAKER_00: Uh your point about patient harm will, if they're going to get across the finish line for injunctive relief, will will hopefully will get them there.
- 14:54SPEAKER_00: And also, hey, Your Honor, look at the mess we have with the clawback from 18 to 22.
- 15:00SPEAKER_00: It's just better to pause this for now so we don't have to do this all over again years from now, right?
- 15:05SPEAKER_00: I mean, this clawback issue has been an issue from the first time.
- 15:10SPEAKER_00: Um what are your thoughts about how the hospitals that back and forth, the advocacy went from 0.5 to 3 down to 2.
- 15:17SPEAKER_00: How are the hospitals thinking about that right now?
- 15:19SPEAKER_01: Yeah, I mean, I think that the reason, just so to explain to our audience why there's a clawback, um the uh this rule or this uh regulation has to be budget neutral, um, which is uh an interesting point because um the hospitals uh are argue, the 340B hospitals argue that this is actually not going to be beneficial um to patients or um or to anyone because uh whatever uh reduction in reimbursement is going to happen on um on drug reimbursement, uh the other hospitals that are not 340B are are gonna get an increase, as well as the 340B hospitals are gonna get an increase on their non-drug payments for Part B programs.
- 16:09SPEAKER_01: So it's it's kind of complicated.
- 16:11SPEAKER_01: The whole clawback thing, it's very difficult to understand.
- 16:15SPEAKER_01: But I think basically CMS felt like had to claw back the money in order to keep this as a budget neutral uh move.
- 16:25SPEAKER_01: Um and uh that is one that is a nuance uh related to this that a lot of people don't understand.
- 16:32SPEAKER_01: So it it's a cut, but then there's actually a reallocation to the entire uh any hospital that gets um payment through the PPS system.
- 16:42SPEAKER_00: So it's which created a little bit of a divide within the hospitals writ large, right?
- 16:47SPEAKER_00: Um, because the for-profit hospitals were like, good, give me my five percent, right?
- 16:51SPEAKER_00: Because the minus 28 created a 7% reallocation the way you described it, but now you're clawing back to.
- 16:57SPEAKER_00: So it this is a great, again, for those nerd for our nerds like you, right?
- 17:02SPEAKER_00: It's a great it's a great, it's very interesting policy.
- 17:05SPEAKER_00: Um and it doesn't just impact the hospitals, right?
- 17:09SPEAKER_00: We have the physician community that also treats obviously patients.
- 17:14SPEAKER_00: Uh and they've always wanted the discount to follow the person.
- 17:18SPEAKER_00: They think that they support this policy because maybe back in the community, uh, why should they get more money than us, right?
- 17:26SPEAKER_00: That's the position of the physicians.
- 17:27SPEAKER_00: How do the hospitals view that dynamic with the physicians?
- 17:32SPEAKER_00: How do they, you know, say, look, yeah, it's okay that we get a 28, 30, 40% spread here, but you docs can.
- 17:40SPEAKER_00: Explain, what is your perspective on that, that positioning of the hospitals?
- 17:44SPEAKER_00: How they, how they um, I don't want to use the word justify, but sort of say, look, yeah, we we in the hospital, we do do this, not the docs.
- 17:52SPEAKER_01: Sure.
- 17:53SPEAKER_01: No, that's a great question.
- 17:55SPEAKER_01: Um, the what the uh hospitals argue um is that they serve a much larger volume of patients that are either low income or disabled.
- 18:07SPEAKER_01: Um, there is um a MedPAC uh study um that found that 54% of the patients, cancer patients served at 340B hospitals, are uh either low income or disabled compared to 34% for the private physician offices.
- 18:26SPEAKER_01: So that's a you know a big difference in the types of patients that are being treated.
- 18:31SPEAKER_01: Also, the hospitals point out that they serve 77% of all Medicaid patients.
- 18:38SPEAKER_01: So it's a um, these are important factors, and the uh the concern uh among the hospital community, particularly the safety net hospital community, is we can't take these cuts at the same time that we're about to go um with uh the big Medicaid cuts that are part of the big beautiful bill.
- 19:00SPEAKER_01: Also, we have the uh the end of the um ACA subsidies for a lot of um Americans who are gonna who are losing their health insurance.
- 19:10SPEAKER_01: Um and it's just uh I would describe it as a potential triple whammy.
- 19:15SPEAKER_01: Um so it's that is the uh concern.
- 19:18SPEAKER_01: Um and the providers in the 340B program would argue that the 340B program was never intended to be a subsidy program for the Medicare program.
- 19:29SPEAKER_01: Um it's intended to uh, you know, there are you do pass on your discounts to the Medicaid program by billing an acquisition cost, but for uh Medicare, um it is not uh it was never intended to be uh something to help the either the Medicare pro program or private insurance.
- 19:50SPEAKER_00: Now, so speaking of which, Ted, right, the other major stakeholder here is the patient, right?
- 19:55SPEAKER_00: Is the Medicare beneficiary.
- 19:57SPEAKER_00: And um they stand to benefit significantly with this P ASP minus 20.
- 20:05SPEAKER_00: So for our listeners, right, that means their coinsurance obligation of 20% is 20% of a much lower number.
- 20:11SPEAKER_00: And so how do the hospitals I get those numbers, okay, doc, right?
- 20:16SPEAKER_00: This is we're very different, but the patient's the patient.
- 20:19SPEAKER_00: And so how do you say to the patient, we need to collect more 20%, you know, of a higher number to cross-subsidize everybody?
- 20:27SPEAKER_00: As does that does that work for the patients, for the beneficiaries?
- 20:31SPEAKER_01: Yeah, I mean, it it it's a an argument that CMS makes um in their press release and in their messaging, but actually what the hospitals say is that 90% of the patients, the Medicare beneficiaries that would be impacted by this already have supplemental insurance, whether that is through their own private supplemental insurance, through the Medicaid program, or through other types of programs that um are there to help patients who um who are gonna absorb these costs.
- 21:08SPEAKER_01: So it's really um and when I talk to the hospital community, they say that this is a red hearing um and that it really is not going to help uh patients.
- 21:20SPEAKER_01: In fact, uh they're gonna end up seeing higher costs on their non-drug um health care expenses.
- 21:27SPEAKER_01: So it's really not a win for patients, is what they would argue.
- 21:32SPEAKER_00: And, you know, um this is gonna shock you coming out of me, right?
- 21:36SPEAKER_00: And I I agree with you completely because I also say that that reduction from whatever it is, minus twenty-eight, at the price point of the drug, the twenty percent of a lower number, is still mostly gonna be unaffordable.
- 21:49SPEAKER_00: If they can't afford Medigap, these patients these beneficiaries, they're not gonna be able to afford the out-of-pocket on a reduced for that drug expense anyway.
- 21:56SPEAKER_00: So I I agree with you that it's sort of a red herring.
- 21:58SPEAKER_00: And just for our listeners to Understand what Ted and I are talking about was discussed in CMS's final rule.
- 22:05SPEAKER_00: And CMS said, well, the reduction will also maybe help Medigap plans reduce their premiums.
- 22:11SPEAKER_00: I don't know if you saw that part of it, Ted.
- 22:14SPEAKER_00: And I actually laughed out loud with the concept of thinking that an insurance that they're going to reduce their premiums to the on the Medigap side.
- 22:22SPEAKER_00: I don't know if you saw that too.
- 22:23SPEAKER_01: I did not see that essence of it.
- 22:26SPEAKER_01: I must say, Jason, you're you're even more of a policy wonk than I am.
- 22:30SPEAKER_01: I did not get through the entire rule.
- 22:33SPEAKER_01: Uh so I'm impressed.
- 22:35SPEAKER_00: I mean, if we could deserve a laugh these days, Ted, I I I you should go and look at that.
- 22:41SPEAKER_00: Now, similarly on this back and forth, you know, and a really interesting question that I've been fielding, and I want to get your response to is well, okay, Jason, wait.
- 22:49SPEAKER_00: You're telling me fee for service is going to reimburse at minus 28.
- 22:54SPEAKER_00: What about Medicare Advantage and what about commercial?
- 22:57SPEAKER_00: Uh we didn't see much of a bleed when it was minus 22 and a half going over to commercial and Medicare Advantage.
- 23:05SPEAKER_00: What are your sources telling you, Ted?
- 23:06SPEAKER_00: Is that likely to happen, not happen?
- 23:08SPEAKER_00: And then I'm happy to share my thoughts on that too.
- 23:11SPEAKER_01: Sure.
- 23:11SPEAKER_01: Um, actually, Jason, I'd be interested in hearing your thoughts because you said that the last time there wasn't that much of uh the private insurance, uh insurers following the lead.
- 23:23SPEAKER_01: Um I don't recall um what happened the last time, and I'd be curious what your thoughts on what might happen this time.
- 23:33SPEAKER_00: I think uh when we and and minus 22 and a half, we didn't see many much market disruption at all, one way or however you look at it.
- 23:40SPEAKER_00: Um when I when they when I'm asked about moving it over to commercial, I find it very hard to believe that the entity will take a lower price.
- 23:53SPEAKER_00: Right, for all the reasons you just said 10 minutes in the last 10, 15 minutes about the way the economics are working in the hospital.
- 24:01SPEAKER_00: So in a hospital near us, right, you go up to Johns Hopkins, which is a major dish hospital, it's not like Aetna United Blue Cross Blue Shield is gonna will be able to say to you, oh, well, Medicare fee for service is 28, we're gonna pay you minus 12, right?
- 24:15SPEAKER_00: I mean, and Hopkins will say, no, we're not a network, right?
- 24:18SPEAKER_00: So I I don't know how that would work.
- 24:20SPEAKER_00: I mean, what uh what do you do what are your thoughts about that?
- 24:23SPEAKER_01: I mean yeah.
- 24:25SPEAKER_01: I think I think it will depend on the hospital.
- 24:28SPEAKER_01: Um, because you know, you mentioned a Johns Hopkins, which is a prestigious academic medical center, and one that has uh market power in Baltimore and is uh one that has uh the ability to maybe have a little bit stronger negotiating uh power than a mid-sized hospital in another part of the country that has a for-profit down the street, that uh has got a larger uh insured population, and it maybe is a bigger player in that market.
- 25:05SPEAKER_01: So I think it's gonna be a case-by-case situation um when it comes to uh the potential for this having um downstream effects.
- 25:15SPEAKER_00: But you haven't heard um the hospitals say, hey, Ted, look, we are concerned, or during the common period, a health plan reached out and said, you know, if this is finalized, we want to renegotiate our 27, or maybe now, right?
- 25:31SPEAKER_00: Well, let's talk about 28.
- 25:32SPEAKER_00: You haven't heard it go that far yet, have you?
- 25:36SPEAKER_01: Well, what I do remember about the last time this occurred is that uh a number of the private insurance plans did um did do some uh lower reimbursement, and now the hospitals are trying to get that that uh money back.
- 25:53SPEAKER_01: Um, there have been some suits against some of the insurers um that thank you for reminding me, um, saying, wait a second, this was deemed illegal by the U.S.
- 26:03SPEAKER_01: Supreme Court.
- 26:04SPEAKER_01: Therefore, uh you owe us money for following um CMS's uh reduction.
- 26:11SPEAKER_01: So I i it it should be interesting to see what will happen.
- 26:15SPEAKER_01: But I know there is certainly a tremendous amount of concern and and frankly fear among the hospitals in the program that they're not gonna be able to handle both the reductions and reimbursement at the same time they're serving more uninsured patients and um and dealing with these uh enormous Medicaid cuts.
- 26:37SPEAKER_00: So it may be, just to sort of wrap up this part uh before we head to the rebate model, right?
- 26:41SPEAKER_00: So what we've learned is hospitals are gonna litigate uh as soon as possible, right?
- 26:46SPEAKER_00: I'm sure the brief is imminent any day now.
- 26:49SPEAKER_00: Uh they're gonna seek injunctive relief.
- 26:52SPEAKER_00: And um back and forth in the preamble is probably a good indicator of what some of the arguments may be.
- 26:58SPEAKER_00: The agency did the survey.
- 27:00SPEAKER_00: Uh, but what I think you just said there at the end will be most interesting.
- 27:04SPEAKER_00: It might be that having if assuming people learn from their history, which is, as you know, right, we know it's dangerous to assume, right, for all the obvious reasons here, that um the commercial may wait to see if this is actually sticks, right?
- 27:17SPEAKER_00: Because of what you just said with the lawsuits.
- 27:19SPEAKER_00: So maybe the right answer for can this go to Medicare Advantage slash commercial more broadly is based upon history, we may not know that until the litigation is fully resolved.
- 27:32SPEAKER_01: That that seems to make sense.
- 27:34SPEAKER_01: I uh I I do think that there's always a chance that we will have uh this, as I mentioned, the deja vu all over again and instances where Medicare Advantage programs and potentially commercial insurers will end up um with uh reducing reimbursement when they can.
- 27:52SPEAKER_01: So um I think it's too early to tell, but we should keep a close eye on it.
- 27:57SPEAKER_00: Absolutely.
- 27:58SPEAKER_00: I love how you keep referencing Yogi Berra, by the way, deja vu all over again.
- 28:02SPEAKER_00: Of course.
- 28:02SPEAKER_01: Well, as you and I know from our discussion prior to this call, I'm a big Red Sox fan and you're a big Yankees fan, but somehow we can still be friends.
- 28:12SPEAKER_00: Yes, very so appreciate that, of course.
- 28:15SPEAKER_00: Um, and so let's speak of litigation of the hospitals, let's talk about the rebate model.
- 28:21SPEAKER_00: Sure.
- 28:22SPEAKER_00: Right?
- 28:22SPEAKER_00: Um and so brief history for our listeners.
- 28:26SPEAKER_00: Um manufacturers that have a maximum fare price are required by law to provide the lower of the 340B price or the maximum fare price at the point of set.
- 28:38SPEAKER_00: So here we are at the 340B entity, and so what the manufacturer wants to do is sort of not have it be an upfront discount, want to make it into a rebate, hence the name rebate model, and has gone back and forth with the oversight agencies, HERSA, with I'm sure some CMS technical expertise in the background, and proposed a rebate model.
- 29:00SPEAKER_00: Um, it was thrown out by the courts, and then CMS went back, excuse me, HERSA went back through the rulemaking, implemented, started another rebate model, and here we are at the litigation.
- 29:12SPEAKER_00: And even the judge has sort of said, hey, Hursa, hey guys, hospitals, right?
- 29:17SPEAKER_00: They do have the authority to do this.
- 29:19SPEAKER_00: Hospitals are suing.
- 29:21SPEAKER_00: Do you expect, how is this going?
- 29:23SPEAKER_00: I mean, do you expect the hospitals to win again?
- 29:25SPEAKER_00: Are they just delaying the inevitable?
- 29:28SPEAKER_00: What give us an update from your side?
- 29:30SPEAKER_00: You're going much closer to hospitals on what's going on with the rebate model and what the hospitals really expect they can ultimately achieve here.
- 29:38SPEAKER_01: Sure.
- 29:38SPEAKER_01: Just to uh to kind of go big picture for a minute, um, as you're aware, Jason, for uh the 34 years that the 340B program has been in uh uh enacted, it's been a program where there is an upfront discount, um, where the providers buy the drug at a very at a low price through the 340B program and then get reimbursed at sometimes a higher price, sometimes at acquisition cost if it's a Medicaid patient.
- 30:10SPEAKER_01: But um it's generally one that has worked uh one way and has worked, uh the providers would argue very effectively.
- 30:19SPEAKER_01: Um and uh so this would be a change, and it would be one that uh the providers are very concerned about uh having to float the costs of these very expensive drugs.
- 30:32SPEAKER_01: They would be buying them at wholesale acquisition cost, which as you're well aware, Jason, is a very high price.
- 30:40SPEAKER_01: Um and um the concern is uh trying to uh eventually get the rebate on these drugs.
- 30:47SPEAKER_01: And so um the drug, uh the um, I'm sorry, the hospital groups once again have sued, um, AHA taking the lead, uh, along with the Maine Hospital Association.
- 30:59SPEAKER_01: That would be Maine up in uh northern New England, um, and uh a number of hospitals uh throughout the country are part of that suit.
- 31:08SPEAKER_01: And they went back to the judge in Maine, who last year ruled in favor of the hospitals and stopped the rebate pilot.
- 31:18SPEAKER_01: And this time they're arguing, okay, um, Hirsa, you might have done a better job of going through the deliberate process of um, you know, making sure that you take in input, that you give enough time for this to be implemented.
- 31:36SPEAKER_01: Um, however, they're arguing you forgot one thing, you ignored all the comments that the providers submitted uh concerning um the rebate pilot.
- 31:46SPEAKER_01: Um they the providers argue that um the comments came in 18 to 1 um ratio against the uh the rebate pilot, and that um that uh CMS, I'm sorry, HERSA gets confused between the two agencies since they're working so closely right now.
- 32:07SPEAKER_01: Um HERSA uh ignored the comments and did not take into any uh into um uh uh consideration the enormous uh costs financially and administrative for the providers in the program to um to change to a rebate program.
- 32:28SPEAKER_01: Um these are 25 different drugs.
- 32:30SPEAKER_01: It's um a lot of time, a lot of energy.
- 32:33SPEAKER_01: And the providers that I talk to, including not just hospitals but community health centers, HIV clinics, say that if we're gonna be spending lots of time submitting data to the drug industry, it takes us away from our day-to-day job, which is treating patients.
- 32:51SPEAKER_01: And so there must be a way to come up and uh come up with a solution that doesn't require so much data submission and so much time with paperwork.
- 33:02SPEAKER_01: And I'm happy to discuss that with you at some point, Jason.
- 33:07SPEAKER_00: But so the the hospitals believe that that is gonna win the day, right?
- 33:14SPEAKER_00: But even though they have these the see Hearst has the authority to allow this to happen on the rebate side, there's another obligation on the other side of that ledger, Ted, right, about giving it to the patient right away at the point of sale, preventing some duplicate discounts.
- 33:28SPEAKER_00: It is also an obligation on the other side on both sides, if you will.
- 33:32SPEAKER_00: Um some of those other public needs, don't those override what we are trying, what they are trying to prevent here at the end.
- 33:41SPEAKER_00: Once they get over the burden or once they get over the hump of implementing it, should be a smooth process and it will be at some point uh seamless.
- 33:52SPEAKER_00: Couldn't it why be why prevent that from happening?
- 33:55SPEAKER_00: It will be better in the long run because of the patient gets what they need right away, the manufacturer's obligated what it is right away.
- 34:03SPEAKER_00: And then to some extent, the hospitals are able to do this and comply with what there's needed on that side.
- 34:08SPEAKER_00: Plus, they're we're doing it on the 340B for CPI and other places.
- 34:13SPEAKER_00: Why so much the resistance here on the rebate model?
- 34:16SPEAKER_00: Give me some more detail on that.
- 34:18SPEAKER_01: Yeah, um, you know, the the hospitals and um and other covered entities, the smaller covered entities like the health community health centers, um, you know, uh HIV clinics, et cetera, et cetera, say that they're already spending so much time submitting data to the drug industry for the different rules that they have related to the contract pharmacy program.
- 34:43SPEAKER_01: And this is just overwhelming.
- 34:45SPEAKER_01: And that it's they're also gonna not only have to hire um additional staff to help um comply with this, but they also have to get vendors, pay vendors to help run these programs.
- 34:59SPEAKER_01: So um the uh HERSA somehow said that it would only take five hours a week to uh to implement the pilot program.
- 35:09SPEAKER_01: And AHA and the other groups have argued that it's gonna take a lot more time than that.
- 35:15SPEAKER_01: Um my sympathy um just from my previous experience is uh to the providers.
- 35:21SPEAKER_01: Um uh but you know, I do do think that there should be ways to address issues such as a duplicate discount that could be potentially more of a win-win um situation.
- 35:34SPEAKER_00: So let's double-click on that for a second, Ted.
- 35:36SPEAKER_00: What would the ha what uh are the hospitals offering any alternative solutions to effectuate the MFP that's not the rebate model?
- 35:46SPEAKER_01: Yeah, um they have argued for what would be described as a neutral clearinghouse.
- 35:51SPEAKER_01: Um it would be uh basically overseen by the government um rather than a drug company.
- 35:58SPEAKER_01: Um, and that information any type of information that would be submitted, claims submission, should go to a third party that is not um uh have any affiliation or uh to the drug industry.
- 36:13SPEAKER_01: Um and that is their, they think would be the way to resolve this issue without having to go through all of the the changes that are going on right now and the the the enormous amount of time that the these providers are spending trying to uh comply with the various requests from the drug industry to submit uh data.
- 36:38SPEAKER_00: Why do you think HERSA has not taken that recommendation?
- 36:41SPEAKER_01: I think HERSA has said that they don't have the authority to go ahead and um move forward with a neutral clearinghouse, um, that it would require Congress to pass legislation that would allow that to go forward.
- 36:58SPEAKER_01: Now, there is um in all of the bills that are currently pending in Congress related to 340B, pretty much all of them include this neutral clearinghouse.
- 37:08SPEAKER_01: Whether any of those bills pass the uh finish line, certainly um before uh the uh lame duck Congress has done is a is an open question.
- 37:19SPEAKER_01: But I do think eventually we're gonna turn to a uh some sort of vendor that is not uh necessarily being paid for by the drug companies, and one that um I think both providers and manufacturers can feel is like an honest broker in this process.
- 37:40SPEAKER_00: When what refresh my recollection on the timing here, um, we're it's already November 9th.
- 37:46SPEAKER_00: It's hard to believe, right?
- 37:48SPEAKER_00: This is we got more draw, right, 27 is around the corner.
- 37:52SPEAKER_00: When will the judge in Maine respond?
- 37:55SPEAKER_00: Is there a timeline here?
- 37:57SPEAKER_01: Yeah, that's a good question, Jason.
- 37:58SPEAKER_01: Um tomorrow's issue of 340B report will have a story that the oral arguments for uh the hospital's uh request for preliminary injunction will occur on November 18th in Portland, Maine.
- 38:14SPEAKER_01: Um, we will have uh one of our reporters, Shannon Young, uh, flo uh uh going up to Portland to cover that those oral arguments.
- 38:23SPEAKER_01: And it'll be a very interesting case because this time around, the drug companies are interveners in the case.
- 38:30SPEAKER_01: Last time around, it was the hospitals versus HERSA, and the hospitals were uh persuasive.
- 38:38SPEAKER_01: Um now the drug companies are going to be part of this uh debate.
- 38:42SPEAKER_01: And the drug companies, as you know, hire hire some of the top lawyers in the nation, some of them who have uh argued many Supreme Court cases before.
- 38:52SPEAKER_01: Um, so it'll be interesting to see how that comes along.
- 38:56SPEAKER_01: Um, but that that we're starting to move forward with the November 18th um oral argument date.
- 39:03SPEAKER_00: And they moved for, like you said, uh injunctive relief such that we expect some decision before the end of the year, right?
- 39:11SPEAKER_00: To state the obvious.
- 39:12SPEAKER_01: Yes.
- 39:12SPEAKER_01: That that that's the goal.
- 39:14SPEAKER_01: Um as you may recall, Jason, last year the decision was made on December 29th, and then it went to the appellate court that I think on January 2nd um made its decision.
- 39:26SPEAKER_01: So um I think you and I may be not exactly having a great time over the holidays.
- 39:33SPEAKER_00: Right.
- 39:33SPEAKER_00: Um Yeah, so speaking of the courts and speaking of the Supreme Courts, let's let's finish up uh our conversation talking a little bit about contract pharmacies.
- 39:44SPEAKER_00: Uh and this emanated from, yeah, again, Trump won, about requiring certain pricing at the contract pharmacy of manufacturers.
- 39:56SPEAKER_00: Uh and so that went to the courts, and the courts said no, um, it can't happen at the feds, and then the state stepped in and the state started passing laws.
- 40:06SPEAKER_00: If you want to do business in this state, you need to provide this price at this litigation ensued.
- 40:13SPEAKER_00: And now we have a split, right?
- 40:15SPEAKER_00: We have the fourth circuit saying dormant commerce clause prevents, and we have other circuits in the country saying, no, the states can do this.
- 40:23SPEAKER_00: Two-part question, Ted.
- 40:24SPEAKER_00: Number one, sort of, did I I characterize that?
- 40:27SPEAKER_00: I I think pretty would correct me if I'm wrong.
- 40:29SPEAKER_00: And then number two, I'm under the understanding, right, that we're gonna the farmers gonna keep litigating, litigating, try to get to the Supreme Court.
- 40:37SPEAKER_00: Uh is that the perception on the other side?
- 40:39SPEAKER_00: I mean, you cover that aside as well.
- 40:42SPEAKER_00: Uh uh is everybody just sort of residing itself to the fact that we're gonna wind up at the Supreme Court here?
- 40:49SPEAKER_01: That's a good question.
- 40:51SPEAKER_01: So um there are 23 states that have passed laws that have basically say drug companies, you cannot impose restrictions on access to 340B discounts so that you um cannot say that you can only get access to 340B pricing at the in-house pharmacy or at one contract pharmacy.
- 41:14SPEAKER_01: Um, you should be allowed to uh patients should be able to get it at any of the contract pharmacies that a provider contracts with.
- 41:24SPEAKER_01: Um those have for the most part been upheld by uh by judges, um, with the exception of the uh Maryland and West Virginia laws.
- 41:35SPEAKER_01: Um those were uh two to one uh uh ruled in favor of the drug industry and said that you're right, that uh that is these laws are preempted by federal law, and that federal law um is uh what determines uh what's going to happen here.
- 41:52SPEAKER_00: Ted, is was the only difference the judge, or was there a substantive difference in the law that led to the outcome?
- 41:58SPEAKER_01: Uh well, I mean, they had different uh arguments and there were a bunch of different uh once again, I'm not a lawyer, but there is stuff about takings and all these other things related to um what's permissible and what is not permissible.
- 42:14SPEAKER_01: And um when does it basically the the main argument that the the that the states have made and the providers have made is that this is a law that is focused on the distribution of drugs, not on the price of drugs.
- 42:29SPEAKER_01: And the drug companies are arguing no, it's actually um sort of an expansion of the 340B program.
- 42:37SPEAKER_01: And um the providers have said, well, we used uh we had contracts with um with various retail partners for 20 some years, and you never had an issue with it, and you're suddenly suing us in 2020.
- 42:52SPEAKER_01: So there is all of these backs and forths.
- 42:55SPEAKER_01: There was a big um appellate court um hearing in Richmond, Virginia, which is the Fourth Circuit.
- 43:02SPEAKER_01: A few weeks ago, the full 15 uh judge panel decided to take on the case, which indicates that there is um some question of whether that two to one decision in favor of the drug industry will actually um uh survive.
- 43:20SPEAKER_01: Um, so that is the one case.
- 43:23SPEAKER_01: If if the jud if the judges rule in favor of um the state, then we're not having a split court, uh split circuit decision.
- 43:33SPEAKER_01: So we shall find out in the next, I would think the next few weeks uh where that that larger panel um subside uh you know decides to go.
- 43:44SPEAKER_01: But the other um all of the other appellate court decisions have been in favor of the states.
- 43:50SPEAKER_00: So, Ted, you've been very generous with your time.
- 43:53SPEAKER_00: I'm gonna get you out of here.
- 43:54SPEAKER_00: We're gonna do a little predictions here, right?
- 43:56SPEAKER_00: We've spent time covering three issues, all heavy.
- 44:00SPEAKER_00: Litigation involved, so we can actually do a um predictions.
- 44:05SPEAKER_00: We can have a little back and forth here.
- 44:07SPEAKER_00: So we covered three issues.
- 44:09SPEAKER_00: All will litigate by the end of the next couple of Supreme Court terms.
- 44:12SPEAKER_00: All all the justices might be better 340B experts than you and me, but the way the way we're going.
- 44:18SPEAKER_00: All right, number one, Ted, right?
- 44:19SPEAKER_00: The hospitals are going to sue on minus 28%.
- 44:23SPEAKER_00: They're going to win or they're going to lose.
- 44:25SPEAKER_00: Well, there's two, right?
- 44:26SPEAKER_00: Are they going to win on uh injunctive relief?
- 44:30SPEAKER_01: Um, I would say that they are going to maybe not win on injunctive relief.
- 44:36SPEAKER_01: Um, and perhaps uh that uh it will continue to be battled through the courts um and maybe we'll make it to the Supreme Court just like the last uh Part B big cut um back uh back in the uh uh 2020.
- 44:50SPEAKER_01: two.
- 44:51SPEAKER_01: So we may have deja vu all over again.
- 44:54SPEAKER_01: I think it was 2018 or 2017 when the cuts went into place.
- 44:57SPEAKER_01: Yeah.
- 44:58SPEAKER_00: Yeah, so that's deja vu all over again over there.
- 45:00SPEAKER_00: All right, number two.
- 45:02SPEAKER_00: We're on the rebate model.
- 45:04SPEAKER_00: Yes.
- 45:04SPEAKER_00: What is your prediction there?
- 45:05SPEAKER_00: That's uh coming.
- 45:07SPEAKER_00: Um and so does that go in or does that get reversed?
- 45:12SPEAKER_01: Um I would say that it will, this is just a prediction that uh that the uh HURSA and the drug companies will potentially win that one.
- 45:24SPEAKER_01: Um whether it gets overturned at the appellate level, we shall see.
- 45:29SPEAKER_01: Um it is um uh an appellate level that I think is pretty sympathetic to the providers in the program, and we'll see if we'll end up at the Supreme Court on that one.
- 45:40SPEAKER_00: And then last but not least, of course, the contract pharmacy.
- 45:43SPEAKER_00: We do have the Richmond.
- 45:45SPEAKER_00: I guess the Richmond is uh is uh is a real wild card, not real wild card here, but a real determining factor here.
- 45:51SPEAKER_00: So maybe the prediction isn't on rich on Supreme Court, but what do you think about what's gonna happen on the Richmond Court?
- 45:58SPEAKER_01: Well, I mean, I listened to the uh oral arguments, and there were some uh some judges that were very uh strongly backing the drug industry side, and there were a few judges that were very vocal on the other side.
- 46:14SPEAKER_01: Um, so it's hard to tell.
- 46:16SPEAKER_01: Um, it was certainly, you know, um, as I mentioned before, the drug companies have really, really top-flight lawyers um who know how to argue these cases.
- 46:26SPEAKER_01: Um, and then you've got these two state lawyers who may not be as uh sophisticated or as um experienced.
- 46:35SPEAKER_01: I thought the state lawyers did a fairly good job, um, but I I it I'd say 50-50 on that one.
- 46:42SPEAKER_01: Um well I'd say a t uh a coin toss on who's gonna win in that in that case.
- 46:47SPEAKER_00: Well, um so thank you, thank you for all of that, Ted.
- 46:51SPEAKER_00: And I I'll I'll say to our listeners that the first place and the best place to find out whether or not Ted was correct is to, of course, go to the 340B report, right?
- 47:01SPEAKER_00: Ted is to get a get a prescrip a subscription to to that.
- 47:05SPEAKER_00: So tell us how we how our listeners can can subscribe.
- 47:08SPEAKER_01: Sure, sure.
- 47:09SPEAKER_01: Um they go to 340breport.com um and then just hit the subscribe button, and we're happy to offer a 25% discount.
- 47:19SPEAKER_01: Um, and we'll provide more details of that to uh Jason and the team um after this conversation.
- 47:28SPEAKER_00: Thank you very much, Ted.
- 47:30SPEAKER_00: And even without the discount, I think there's a lot of value in in the 340B report.
- 47:34SPEAKER_00: So we appreciate you offering that um to our listeners.
- 47:37SPEAKER_00: And with that, thank you all for participating and for listening.
- 47:41SPEAKER_00: And Ted, uh I look forward to seeing if your predictions come true.
- 47:46SPEAKER_00: Thank you very much.
- 47:47SPEAKER_00: Okay, great.
- 47:47SPEAKER_00: Thanks.
- 47:48SPEAKER_00: Take care, Jason.
- 47:49SPEAKER_00: That wraps up this episode of Value-Based Voices brought to you by the Association for Value-Based Cancer Care.
- 47:54SPEAKER_00: Thank you so much, Ted, for joining us on such short notice to share your insights and your predictions on the 340B program.
- 48:03SPEAKER_00: And of course, to our listeners for joining the conversation.
- 48:07SPEAKER_00: If you found today's discussion thought-provoking, be sure to subscribe to Value Based Voices wherever you get your podcasts.
- 48:14SPEAKER_00: Also subscribe to the 340B report where you can see whether or not Ted's predictions come true.
- 48:19SPEAKER_00: And please stay tuned for more episodes at Spotlight the Voices Shaping the Future of Cancer Care.